Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;205(3):947-955.
doi: 10.1111/bjh.19491. Epub 2024 May 2.

Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy

H F Robertson  1   2 , D Milojkovic  1   2 , N Butt  3 , J Byrne  4 , S Claudiani  1   2 , M Copland  5 , P Gallipoli  6 , A J Innes  1   2 , K Knight  3 , A J Mahdi  7 , J Parker  8 , A Virchis  9 , J F Apperley  1   2
Affiliations

Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy

H F Robertson et al. Br J Haematol. 2024 Sep.

Abstract

Diagnosing chronic myeloid leukaemia (CML) during pregnancy is rare. Tyrosine kinase inhibitors (TKIs) have traditionally been contraindicated owing to their teratogenicity. Management decisions should consider the risks to mother and foetus of uncontrolled disease and teratogenic medications. Further cases are required to build upon the paucity of current literature. We report 22 cases of CML diagnosed during pregnancy from 2002 to date. Twenty-one pregnancies resulted in healthy babies and one patient miscarried. Some patients remained untreated throughout pregnancy but the majority received one or both of interferon-α and leucapheresis. One patient was started on imatinib at Week 26, and one on hydroxycarbamide in the third trimester. We report haematological parameters during pregnancy to provide clinicians with realistic expectations of management. There were no fetal abnormalities related to treatment during pregnancy. Seventeen patients achieved at least major molecular response on first-line TKI. A diagnosis of CML during pregnancy can be managed without significant consequences for mother or child. Leucapheresis and interferon-α are generally safe throughout pregnancy. Despite having been avoided previously, there is growing evidence that certain TKIs may be used in particular circumstances during the later stages of pregnancy. Future work should aim to further elucidate this safety profile.

Keywords: chronic myeloid leukaemia; pregnancy.

PubMed Disclaimer

References

REFERENCES

    1. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–2857.
    1. Robertson HF, Apperley JF. Treatment of CML in pregnancy. Hematology Am Soc Hematol Educ Program. 2022;2022(1):123–128.
    1. Robertson HF, Buckton MJ, Apperley JF. Managing women of childbearing age with chronic myeloid leukemia: safety and treatment considerations. Expert Rev Hematol. 2023;16(5):325–332.
    1. Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Ther Adv Hematol. 2020;11:2040620720966120.
    1. Abruzzese E, de Fabritiis P, Trawinska MM, Niscola P, Apperley JF, Mauro MJ. Back to the future: treatment‐free remission and pregnancy in chronic myeloid leukemia. Eur J Haematol. 2019;102(2):197–199.

MeSH terms

LinkOut - more resources